Navigation Links
Separating a cancer prevention drug from heart disease risk

Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?

Researchers at Winship Cancer Institute of Emory University have identified a way that celecoxib (Celebrex) pushes cancer cells into suicide, separately from its known effects. The Winship team's results outline a route to alternatives to celecoxib that keep its cancer-preventive properties while avoiding its risks.

Celecoxib's risk profile has confined its use to people who have inherited cancer risk or those who have had cancer already. Its effectiveness at stopping tumor progression and recurrence is being tested in several clinical trials for people who have had lung, head and neck and other types of cancer.

Shi-Yong Sun, PhD, and colleagues report in an upcoming issue of the journal Cancer Research that celecoxib inhibits an enzyme called GSK3 (glycogen synthase kinase 3) in lung cancer cells. This causes the disappearance of a protein called c-FLIP, which usually staves off apoptosis, a form of cellular suicide.

"We have been focusing on how celecoxib induces c-FLIP degradation and apoptosis in cancer cells, independent of COX-2 inhibition," Sun says.

Scientists think that celecoxib's ability to inhibit COX-2 enzymes is the basis for its anti-inflammatory properties as well as its influence on heart disease.

Sun is professor of hematology and medical oncology at Emory University School of Medicine and a Georgia Cancer Coalition Distinguished Cancer Scholar. The first author of the paper, postdoc Shuzhen Chen, is now at the Chinese Academy of Medical Sciences' Institute of Medicinal Biotechnology in Beijing. Fadlo Khuri, MD, deputy director of Winship Cancer Institute, is a co-author on the paper.

The result was surprising partly because until a few years ago, scientists thought that inhibiting GSK3, while possibly helpful in diseases such as diabetes, could promote cancer. However, recent results suggest that blocking GSK3 may stop cell growth in prostate, pancreatic and colon cancers and some types of leukemia.

Sun cautions: "We do not know whether GSK3 inhibition by celecoxib has anything to do with celecoxib's cardiovascular risk."


Contact: Holly Korschun
Emory University

Related medicine news :

1. Web tool aims to improve the workplace for breast cancer survivors
2. IUD reduces the risk of cervical cancer
3. IUDs May Lower Womens Risk for Cervical Cancer: Study
4. Women With BRCA Mutations Get Cancer Diagnosis Earlier Than Before
5. NSAID Painkillers Linked to Risk of Kidney Cancer
6. X-ray protein probe leads to potential anticancer tactic
7. Lung cancer signatures in blood samples may aid in early detection
8. Women who inherit BRCA gene mutations develop cancer earlier than their ancestors
9. Breast cancer patients with BRCA gene diagnosed almost 8 years earlier than generation before
10. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
11. Talking -- or Not Talking -- Can Give Cancer Patients a Sense of Control
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: